The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Cited by
Sorted by citations
Items 401–500 of 1,006
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 63
Wu, H., Yao, H., He, C., Jia, Y., Zhu, Z., Xu, S., Li, D., & Xu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.019 · Cited by 63
Inborn errors of human IKAROS: LOF and GOF variants associated with primary immunodeficiency
Kuehn, H. S., Boast, B., & Rosenzweig, S. D. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac109 · Cited by 60
Huh, H. D., Sub, Y., Oh, J., Kim, Y. E., Lee, J. Y., Kim, H.-R., Lee, S., Lee, H., Pak, S., Amos, S. E., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01753-7 · Cited by 63
Wang, Z., Shaabani, S., Gao, X., Ng, Y. L. D., Sapozhnikova, V., Mertins, P., Krönke, J., & Dömling, A. S. S. (2023) · Nature Communications · doi:10.1038/s41467-023-43614-3 · Cited by 70
Self-citationRychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J. C., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 61
Ramachandran, S., & Ciulli, A. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.10.009 · Cited by 62
The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigmaPreprint
Georgopoulos, K. (2017) · Genes & Development · doi:10.1101/gad.297002.117 · Cited by 69
PAX3-FOXO1: Zooming in on an “undruggable” target
Wachtel, M., & Schäfer, B. W. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.006 · Cited by 57
Immunopathogenesis and immunotherapy of multiple myeloma
Tamura, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2405-7 · Cited by 59
Vleet, T. R. V., Liguori, M. J., Lynch, J. J., Rao, M. S., & Warder, S. E. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218799713 · Cited by 61
Structural Biology of CRL Ubiquitin Ligases
Rusnac, D.-V., & Zheng, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_2 · Cited by 54
Misund, K., Bruinink, D. H. O., Coward, E., Hoogenboezem, R. M., Rustad, E. H., Sanders, M. A., Rye, M. B., Sponaas, A., van der Holt, B., Zweegman, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01597-y · Cited by 56
Novel approaches to targeted protein degradation technologies in drug discovery
Xue, Y., Bolinger, A. A., & Zhou, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2187777 · Cited by 59
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 59
Aubrey, B. J., Cutler, J. A., Bourgeois, W., Donovan, K. A., Gu, S. S., Hatton, C., Perlee, S. C., Perner, F., Rahnamoun, H., Theall, A. C. P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 58
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 55
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
Uckun, F. M. (2021) · Cancers · doi:10.3390/cancers13092018 · Cited by 57
Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
Gosavi, P. M., Ngan, K. C., Yeo, M. J. R., Su, C., Li, J., Lue, N. Z., Hoenig, S. M., & Liau, B. B. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01603 · Cited by 56
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56
Geiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 57
Screening for molecular glues – Challenges and opportunities
Holdgate, G. A., Bardelle, C., Berry, S. K., Lanne, A., & Cuomo, M. E. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.008 · Cited by 60
Gao, J., Buckley, S. M., Cimmino, L., Guillamot, M., Strikoudis, A., Cang, Y., Goff, S. P., & Aifantis, I. (2015) · eLife · doi:10.7554/elife.07539 · Cited by 56
Maura, F., Boyle, E. M., Coffey, D. G., Maclachlan, K. H., Gagler, D. C., Diamond, B. T., Ghamlouch, H., Blaney, P., Ziccheddu, B., Cirrincione, A. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00657-1 · Cited by 59
Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen‐Kiang, S., Jaffrey, S. R., & Xu, G. (2015) · The FASEB Journal · doi:10.1096/fj.15-274050 · Cited by 55
Akuffo, A. A., Alontaga, A. Y., Metcalf, R. S., Beatty, M. S., Becker, A., McDaniel, J. M., Hesterberg, R. S., Goodheart, W. E., Gunawan, S., Ayaz, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816868 · Cited by 55
Burslem, G. M., Ottis, P., Jaime‐Figueroa, S., Morgan, A. R., Cromm, P. M., Toure, M., & Crews, C. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800271 · Cited by 54
Harding, T., Baughn, L. B., Kumar, S. K., & Ness, B. V. (2019) · Leukemia · doi:10.1038/s41375-018-0362-z · Cited by 56
Targeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 55
Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade
Lill, J. R., Mathews, W. R., Rose, C. M., & Schirle, M. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1962300 · Cited by 57
Steinebach, C., Bricelj, A., Murgai, A., Sosič, I., Bischof, L., Ng, Y. L. D., Heim, C., Maiwald, S. A., Proj, M., Voget, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00851 · Cited by 57
Self-citationNakayama, Y., Kosek, J., Capone, L., Hur, E. M., Schafer, P. H., & Ringheim, G. E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601725 · Cited by 54
Protein-slaying drugs could be the next blockbuster therapies
Scudellari, M. (2019) · Nature · doi:10.1038/d41586-019-00879-3 · Cited by 56
Decoding the messaging of the ubiquitin system using chemical and protein probes
Henneberg, L. T., & Schulman, B. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.009 · Cited by 53
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 61
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Luo, X., Archibeque, I., Dellamaggiore, K., Smither, K., Homann, O. R., Lipford, J. R., & Mohl, D. A. (2022) · iScience · doi:10.1016/j.isci.2022.103985 · Cited by 55
Cereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 53
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 56
Self-citationUbiquitin-Dependent Regulation of Stem Cell Biology
Werner, A. A., Manford, A. G., & Rapé, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.002 · Cited by 52
Takahashi, K., Hu, B., Wang, F., Yan, Y., Kim, E., Vitale, C., Patel, K. P., Strati, P., Gumbs, C. E., Little, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-817296 · Cited by 51
A mass spectrometry-based proteome map of drug action in lung cancer cell lines
Ruprecht, B., Bernardo, J. D., Wang, Z., Mo, X., Ursu, O., Christopher, M., Fernandez, R. B., Zheng, L., Dill, B. D., Wang, H., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0572-3 · Cited by 53
Zhong, Y., Chi, F., Wu, H., Liu, Y., Xie, Z., Huang, W., Shi, W., & Qian, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114142 · Cited by 52
Confounding Factors in Targeted Degradation of Short-Lived Proteins
Vetma, V., Perez, L. C., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00152 · Cited by 53
Pak, C., Callander, N. S., Young, E. W. K., Titz, B., Kim, K., Saha, S., Chng, K., Asimakopoulos, F. A., Beebe, D. J., & Miyamoto, S. (2015) · Integrative Biology · doi:10.1039/c5ib00071h · Cited by 52
Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 52
Díaz, T., Rodríguez, V., Lozano, E., Mena, M.-P., Calderón, M., Rosiñol, L., Martı́nez, A., Tovar, N., Pérez‐Galán, P., Bladé, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.164632 · Cited by 52
Ushering in the next generation of precision trials for pediatric cancer
DuBois, S. G., Corson, L., Stegmaier, K., & Janeway, K. A. (2019) · Science · doi:10.1126/science.aaw4153 · Cited by 53
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C., Prince, H. M., & Neeson, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632399 · Cited by 52
Silva, M. C., Nandi, G., Donovan, K. A., Cai, Q., Berry, B. C., Nowak, R. P., Fischer, E. S., Gray, N. S., Ferguson, F. M., & Haggarty, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.801179 · Cited by 51
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
Tanenbaum, B., Miett, T., & Patel, S. A. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05058-5 · Cited by 57
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51
Weiss, M. M., Zheng, X., Ji, N., Browne, C. M., Campbell, V. T., Chen, D., Enerson, B., Fei, X., Huang, X., Klaus, C. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01823 · Cited by 52
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 51
Self-citationPrecision medicine: from pharmacogenomics to pharmacoproteomics
Chambliss, A. B., & Chan, D. W. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9127-8 · Cited by 52
Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 52
Ullah, K., Zubia, E., Narayan, M., Yang, J., & Xu, G. (2018) · FEBS Journal · doi:10.1111/febs.14708 · Cited by 53
The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
Mougiakakos, D., Bach, C., Böttcher, M., Beier, F., Röhner, L., Stoll, A., Rehli, M., Gebhard, C., Lischer, C., Eberhardt, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0555 · Cited by 51
Self-citationCereblon enhancer methylation and IMiD resistance in multiple myeloma
Haertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Vogt, C., Alonso, R., Bittrich, M., Ruiz‐Heredia, Y., Vià, M. D., et al. (2021) · Blood · doi:10.1182/blood.2020010452 · Cited by 51
Self-citationAdvancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
Ruffilli, C., Röth, S., Rodrigo, M., Boyd, H., Zelcer, N., & Moreau, K. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00142 · Cited by 51
Proteomic characterization of post-translational modifications in drug discovery
Zhai, L., Chen, K., Hao, B., & Tan, M. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01017-y · Cited by 53
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
Michaelides, I. N., & Collie, G. W. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01882 · Cited by 51
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation
Basu, A. A., Zhang, C., Riha, I. A., Magassa, A., Campos, M. A. L., Caldwell, A. G., Ko, F., & Zhang, X. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01655-9 · Cited by 53
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
North, B. J., Almeciga-Pinto, I., Tamang, D., Yang, M., Jones, S. S., & Quayle, S. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173507 · Cited by 49
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell
Sayed, N., Ameen, M., & Wu, J. C. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz024 · Cited by 51
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Pazina, T., James, A. M., Colby, K. B., Yang, Y., Gale, A., Jhatakia, A., Kearney, A. Y., Graziano, R. F., Bezman, N., Robbins, M. D. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0579 · Cited by 50
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49
Self-citationMathien, S., Tesnière, C., & Meloche, S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000170 · Cited by 51
IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors
Zou, Y., Liu, B., Li, L., Yin, Q., Tang, J., Jing, Z., Huang, X., Zhu, X., & Chi, T. H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.016 · Cited by 49
The resurgence of phenotypic screening in drug discovery and development
Wagner, B. K. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1122589 · Cited by 53
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications
Sang, Y., Fan, Y., & Ren, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6052 · Cited by 50
Jones, R. J., Iempridee, T., Wang, X., Lee, H. C., Mertz, J. E., Kenney, S. C., Lin, H. C., Baladandayuthapani, V., Dawson, W. O., Shah, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2242 · Cited by 48
Yang, J., Huang, M. J., Zhou, L., He, X., Jiang, X., Zhang, Y., & Xu, G. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002246 · Cited by 48
Emerging Roles of SKP2 in Cancer Drug Resistance
Wu, T., Gu, X., & Cui, H. (2021) · Cells · doi:10.3390/cells10051147 · Cited by 49
Chen, J., Zhu, W., Liu, J., Wang, G., Chen, X., Tan, Y., Xu, W., Qu, L.-W., Li, J., Yang, H.-J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00811-0 · Cited by 52
Molecular glues to stabilise protein–protein interactions
Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 49
Targeting ubiquitination in disease and therapy
Yang, X., Lan, T., Zhang, B., Tao, X., Qi, W., Xie, K., Cai, Y., Liu, C., Han, J., & Wu, H. M. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02392-8 · Cited by 55
Neri, P. E., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 49
Čermáková, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 51
Chung, C.-I., Zhang, Q., & Shu, X. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03476 · Cited by 44
Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
Renneville, A., Gasser, J. A., Grinshpun, D. E., Beltran, P. M. J., Udeshi, N. D., Matyskiela, M. E., Clayton, T., McConkey, M. E., Viswanathan, K., Tepper, A., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0105 · Cited by 46
Self-citationTargeting post-translational modification of transcription factors as cancer therapy
Qian, M., Yan, F., Yuan, T., Yang, B., He, Q., & Zhu, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.005 · Cited by 47
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 50
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Ichikawa, S., Payne, N. C., Xu, W., Chang, C., Vallavoju, N., Frome, S., Flaxman, H. A., Mazitschek, R., & Woo, C. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.003 · Cited by 49
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma
Auner, H. W., & Cenci, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13172 · Cited by 49
Transcription Factor Repertoire of Homeostatic Eosinophilopoiesis
Bouffi, C., Kartashov, A. V., Schollaert, K. L., Chen, X., Bacon, W. C., Weirauch, M. T., Barski, A., & Fulkerson, P. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500510 · Cited by 48
Yeh, Y.-Y., Chen, R., Hessler, J. D., Mahoney, E., Lehman, A. M., Heerema, N. A., Grever, M. R., Plunkett, W. K., Byrd, J. C., & Johnson, A. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2096 · Cited by 47
The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis
Xu, Y., Zhang, Z., Li, J., Tong, J., Cao, B., Taylor, P. P., Tang, X., Wu, D., Moran, M. F., Zeng, Y., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0499-7 · Cited by 47
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 48
Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid
Chen, X., Zhang, X., Cai, H., Yang, W., Lei, H., Xu, H., Wang, W., Zhu, Q., Kang, J., Tong, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.015 · Cited by 45
Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
Wang, Z., Zhou, G., Na, R., Fu, J., Zou, Y., Tang, J., Li, L., Liu, H., Liu, Q., & Zhu, X. (2020) · Cell Transplantation · doi:10.1177/0963689720920825 · Cited by 47
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
Self-citation
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
